MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $256.17 million. The enterprise value is $105.95 million.
| Market Cap | 256.17M |
| Enterprise Value | 105.95M |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 62.63 million shares outstanding. The number of shares has increased by 0.78% in one year.
| Shares Outstanding | 62.63M |
| Shares Change (YoY) | +0.78% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 2.65% |
| Owned by Institutions (%) | 112.28% |
| Float | 54.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.91 |
| Forward PS | 5.02 |
| PB Ratio | 2.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.63, with a Debt / Equity ratio of 0.32.
| Current Ratio | 3.63 |
| Quick Ratio | 3.43 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.19 |
Financial Efficiency
Return on equity (ROE) is -14.90% and return on invested capital (ROIC) is -130.96%.
| Return on Equity (ROE) | -14.90% |
| Return on Assets (ROA) | -7.80% |
| Return on Capital (ROIC) | -130.96% |
| Revenue Per Employee | $127,897 |
| Profits Per Employee | -$68,552 |
| Employee Count | 339 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 5.13 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.42% in the last 52 weeks. The beta is 2.08, so MacroGenics's price volatility has been higher than the market average.
| Beta (1Y) | 2.08 |
| 52-Week Price Change | -12.42% |
| 50-Day Moving Average | 12.34 |
| 200-Day Moving Average | 10.22 |
| Relative Strength Index (RSI) | 25.11 |
| Average Volume (30 Days) | 2,565,280 |
Short Selling Information
The latest short interest is 8.89 million, so 14.19% of the outstanding shares have been sold short.
| Short Interest | 8.89M |
| Short Previous Month | 9.96M |
| Short % of Shares Out | 14.19% |
| Short % of Float | 16.23% |
| Short Ratio (days to cover) | 2.44 |
Income Statement
In the last 12 months, MacroGenics had revenue of $43.36 million and -$23.24 million in losses. Loss per share was -$0.39.
| Revenue | 43.36M |
| Gross Profit | 36.54M |
| Operating Income | -183.57M |
| Pretax Income | -23.24M |
| Net Income | -23.24M |
| EBITDA | -9.66M |
| EBIT | -21.33M |
| Loss Per Share | -$0.39 |
Balance Sheet
The company has $184.24 million in cash and $34.01 million in debt, giving a net cash position of $150.23 million or $2.40 per share.
| Cash & Cash Equivalents | 184.24M |
| Total Debt | 34.01M |
| Net Cash | 150.23M |
| Net Cash Per Share | $2.40 |
| Equity / Book Value | 106.15M |
| Book Value Per Share | 1.69 |
| Working Capital | 146.81M |
Cash Flow
In the last 12 months, operating cash flow was -$111.02 million and capital expenditures -$2.80 million, giving a free cash flow of -$113.82 million.
| Operating Cash Flow | -111.02M |
| Capital Expenditures | -2.80M |
| Free Cash Flow | -113.82M |
| FCF Per Share | -$1.83 |
Margins
Gross margin is 84.28%, with operating and profit margins of -423.39% and -53.60%.
| Gross Margin | 84.28% |
| Operating Margin | -423.39% |
| Pretax Margin | -53.60% |
| Profit Margin | -53.60% |
| EBITDA Margin | -22.29% |
| EBIT Margin | -49.20% |
| FCF Margin | -262.51% |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.78% |
| Shareholder Yield | -0.78% |
| Earnings Yield | -9.07% |
| FCF Yield | -44.43% |
Analyst Forecast
The average price target for MacroGenics is $12.44, which is 204.16% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.44 |
| Price Target Difference | 204.16% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 37.28% |
| EPS Growth Forecast (5Y) | 56.94% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -4.83 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.83 |
| Piotroski F-Score | 1 |